Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07213843

Combined Circulatory and Dietary Interventions for Neuropathy

The purpose of this study is to evaluate the effectiveness of three different interventions in improving neuropathy symptoms in individuals aged 35-85 with moderate to severe neuropathy. The study will compare three treatment groups: Intraneural Facilitation® (INF®) therapy alone, INF® therapy combined with Neuro vascular index (NVI) food-guided elimination (NVIf), and NVIf alone. The aim is to determine which treatment results in the greatest improvement in neuropathy symptoms, including quality of life, sensory and pain improvements, and functional outcomes.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

35 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

The purpose of this investigator-initiated study is to observe the effectiveness of a manual physical therapy technique known as Intraneural Facilitation (INF®), both independently and in combination with a Nutritional Vascular Inflammation focused (NVIf) dietary intervention, in improving neurovascular function, pain, and physical performance in individuals with moderate to severe peripheral neuropathy (PN). Subjects will be randomized into one of the three interventions arms: (1) INF® therapy alone, (2) NVIf intervention alone or (3) a combination of both. INF® is a manual therapy, while NVIf utilizes ultrasound guided food elimination. Outcomes include pain (Visual analog scale), sensory function (Semmes Weinstein Monofilament), physical function (Lower extremity functional scale, 10-meter walk test, timed up and go) quality of life (Norfolk Quality of life-Diabetic neuropathy), and neurovascular blood flow analysis. Study participants will be 35-85 years old with a physician-confirmed diagnosis of moderate to severe lower extremity peripheral neuropathy and at least one symptom: numbness, tingling, burning, sharp pain, or increased sensitivity. They must score 0-60 on the Lower Extremity Functional Scale (LEFS), speak and understand English, provide written informed consent, and be willing to complete all study procedures, including intervention and follow-up visits. Participants must be able to ambulate independently with or without an assistive device. Subjects will be recruited using email and flyer through the Neuropathic Therapy Center (NTC) research interest list and through providers at Loma Linda's University (LLU) Health offices. 60 subjects will be recruited, and consent will take place at the LLU or at the Murrieta study site prior to randomization, administered by trained study staff authorized to obtain informed consent.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed diagnosis of peripheral neuropathy in the lower extremities by a physician
  • Lower Extremity Functional Scale (LEFS) score between 0-60 (indicating moderate to significant difficulty in lower extremity function)
  • Ability to speak and understand English
  • Ability to provide appropriate written informed consent
  • Willingness to participate in all study procedures, including the intervention and follow-up visits
  • Ability to ambulate independently with or without an assistive device

Exclusion criteria

  • Any medical condition suggesting potential decline in function over the next 6 months (e.g., ongoing chemotherapy, radiation therapy, or dialysis)
  • Active alcohol or drug misuse
  • End-stage renal failure
  • Uncontrolled hypertension
  • Severe dyslipidemia
  • Chronic liver disease
  • Autoimmune disease
  • Advanced chronic obstructive pulmonary disease (COPD)
  • Active inflammation
  • Shingles-related neuropathy
  • Presence of any lower extremity amputations or significant wounds
  • Severe chronic medical conditions requiring active treatment that could interfere with study outcomes
  • Morbid obesity
  • Concomitant use of medications or devices that may interfere with study results or are not allowed per protocol
  • Inability to comprehend or provide informed consent
  • Inability to speak or understand English
  • Pregnancy, breastfeeding, or planning pregnancy during the study period (female participants)
  • Inability or unwillingness to adhere to study procedures, including dietary guidelines or follow-up visits
  • Inability to complete all required study assessments, including follow-up appointments and questionnaires

Treatment and study plan

INF® Therapy

Other

INF® therapy is a manual technique designed to improve neural circulation by using a series of manual holds administered by a trained practitioner,

Other names: Intranerual Facilitation

NVIf

Other

NVIf is a dietary intervention that uses a patented ultrasound technology to assess vascular responses to food allergens

Other names: Neuro vascular index food-guided elimination

Primary outcomes

  1. Change in Pain Intensity

    Time frame: Baseline (Week 0) and post-intervention (Week 4-5)

    Pain intensity will be assessed using the Visual Analog Scale. Improvement will be indicated by reduced VAS scores. Unit of Measure: Millimeters on a 0-100 mm scale.

  2. Change in Sensory Function

    Time frame: Baseline (Week 0), mid-treatment (Week 3), and post-intervention (Week 4-5)

    Sensory function will be assessed using the Semmes-Weinstein Monofilament test. Improvement will be indicated by increased monofilament detection. Detection threshold in grams (monofilament response: detected/not detected)

  3. Change in Functional Limitation

    Time frame: Baseline (Week 0) and post-intervention (Week 4-5)

    Functional limitation related to neuropathy will be assessed using the Lower Extremity Functional Scale. Improvement will be indicated by higher Lower Extremity Functional Scale scores. Scale score (0-80).

  4. Change in Gait Speed

    Time frame: Baseline (Week 0), mid-treatment (Week 3), and post-intervention (Week 4-5)

    Gait speed will be assessed using the 10-Meter Walk Test. Improvement will be indicated by faster walk time. Seconds to complete 10 meters (converted to meters/second if applicable)

  5. Change in Mobility and Fall Risk

    Time frame: Baseline (Week 0), mid-treatment (Week 3), and post-intervention (Week 4-5)

    Mobility and fall risk will be assessed using the Timed Up and Go (TUG) test. Improvement will be indicated by shorter completion times. Unit of Measure: Seconds.

Secondary outcomes

  1. Change in Quality of Life

    Time frame: Baseline (Week 0) and post-intervention (Week 4-5)

    Quality of life will be measured using the Norfolk Quality of Life-Diabetic Neuropathy questionnaire to determine the effect of each treatment approach on overall patient well-being. Higher scores indicate greater impairment; a reduction reflects improved quality of life. Lowest score=0, means best quality of life with little to no neuropathy impacts. A maximum score of 138, means worst quality of life with severe impairments.

Other outcomes

  1. Change in Neurovascular Function and Inflammation

    Time frame: Baseline (Week 0) and post-intervention (Week 4-5)

    Mechanistic analysis will be performed using the Neurovascular Index with Philips Affinity 50 Ultrasound to evaluate changes in microvascular resistance and neurovascular blood flow, as well as the effect of NVI-guided food elimination on reducing neurovascular inflammation.

Study contacts

Contact information is provided by the study sponsor or research team.

Kyan Sahba, Post Doctoral Fellow, PhD

CONTACT

[email protected]

9095586799

Mark Bussell, Clinical Director, DPT

CONTACT

[email protected]

9095586799

Sponsors and collaborators

Lead sponsor

Loma Linda University

Other

Registry information

Official study title

Combined Circulatory and Dietary Interventions for Neuropathy (CDIN)

Acronym: CDIN

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Oct 9, 2025
Registry last updated
Oct 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.